SAN DIEGO--(BUSINESS WIRE)--The following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego, CA:

• Androgen deprivation therapy by a gonadotropin releasing hormone antagonist, degarelix, lowers the risk of cardiovascular events or death when compared to luteinising hormone-releasing agonists (Abstract 781)
  
  Date: Monday, May 6, 2013; 8:00-10:00 AM
  Session/Type: Prostate Cancer: Advanced (II); Moderated Poster
  Location: San Diego Convention Center, Room 7
  Authors: Peter Albertsen; Bertrand Tombal; Thomas Wiegel; Egbert van der Meulen; Bo-Eric Persson; Tine Kold Olesen; Joshua Beckman
• Analysis of disease control-related outcomes from six comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists (Abstract 716)
  
  Date: Sunday, May 5, 2013; 3:30-5:30 PM
  Session/Type: Prostate Cancer: Advanced (I); Podium Presentation
  Location: San Diego Convention Center, Room 1
  Authors: Neal Shore; Kurt Miller; Bertrand Tombal; E. David Crawford; Cathrina Karup; Egbert van der Meulen; Bo-Eric Persson

Per AUA media embargo policy, coverage of research being presented is prohibited before the date and time of presentation.

About Ferring

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries. To learn more about Ferring or its products, please visit www.ferring.com.

© 2013 Ferring B.V.

FIRMAGON^® is a registered trademark of Ferring B.V.